Vision therapy helps brain injury patients

Article

Stroke and traumatic brain injury survivors, who have undergone vision restoration therapy (VRT), demonstrate increased brain activity, according to researchers from Columbia University Medical Center, USA.

Stroke and traumatic brain injury survivors, who have undergone vision restoration therapy (VRT), demonstrate increased brain activity, according to researchers from Columbia University Medical Center, USA.

Randolph Marshall and colleagues examined the functional magnetic resonance imaging (fMRIs) of six patients aged between 35 and 77 with homonymous hemianopia vision loss caused by stroke or traumatic brain injury. Each patient underwent VRT therapy to help rehabilitate their vision.

The fMRI data showed that there was an increased activity in the visual processing areas of the brain as patients learned to detect stimuli in the border zone between the seeing and non-seeing fields. This enhanced activity was identified one month after the start of treatment, suggesting that the brain responds accordingly.

The treatment involves patients performing daily therapy at home for between six and seven months, gradually improving their vision through repeated detection of light stimuli directed at the border between the seeing and blind areas of the visual field.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.